STOK Earnings & Financial Statements
Stoke Therapeutics, Inc.
$23.26
+$0.76(+3.38%)
40
Overall
50
Value
18
Tech
52
Quality
Market Cap
$1.50B
Volume
1.01M
52W Range
$20.32 - $40.22
Target Price
$46.44
STOK earnings and financial statements: Stoke Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
STOK Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $184.42M | $36.55M | $8.78M | $12.40M | - |
| Operating income | -$20.59M | -$101.37M | -$114.77M | -$104.36M | -$86.06M |
| EBITDA | -$18.84M | -$99.42M | -$102.47M | -$102.81M | -$85.09M |
| Net income | -$6.88M | -$88.98M | -$104.70M | -$101.07M | -$85.81M |
| EPS (diluted) | $-0.12 | $-1.65 | $-2.38 | $-2.60 | $-2.34 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $418.43M | $271.56M | $228.34M | $256.07M | $238.87M |
| Total liabilities | $65.98M | $42.53M | $68.78M | $71.22M | $21.09M |
| Shareholders’ equity | $352.46M | $229.02M | $159.56M | $184.85M | $217.78M |
| Cash and equivalents | $84.22M | $127.98M | $191.44M | $113.56M | $144.90M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $45.59M | -$86.85M | -$81.07M | -$31.87M | -$66.91M |
| Capital expenditure | -$670.0K | -$203.0K | -$1.62M | -$3.96M | -$1.20M |
| Free cash flow | $44.91M | -$87.05M | -$82.68M | -$35.83M | -$68.11M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | STOK | $23.26 | +3.4% | 1.01M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Stoke Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW